诚达药业(301201) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 108,619,193.47, representing a 23.54% increase compared to CNY 87,920,036.48 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 26,229,854.86, up 25.28% from CNY 20,937,541.64 in Q1 2021[3] - Sales revenue for the first quarter of 2022 reached RMB 101,851,387.79, an increase of 34.19% compared to RMB 75,901,381.67 in the same period last year[8] - The company reported a net profit increase, leading to a 30.01% rise in income tax expenses, totaling RMB 4,713,058.02[8] - Net profit for Q1 2022 reached CNY 26,213,014.63, representing a 25.5% increase from CNY 20,898,666.42 in Q1 2021[23] Cash Flow - The net cash flow from operating activities was negative CNY 4,239,687.31, a decline of 132.91% compared to CNY 12,883,251.85 in the previous year[3] - Cash flow from operating activities saw a substantial increase, with cash received from other operating activities rising by 776.52% to RMB 9,918,069.62, mainly due to higher export tax rebates[8] - Cash inflow from operating activities totaled CNY 111,769,457.41, compared to CNY 77,032,906.78 in the same period last year[25] - The total cash outflow from operating activities was 116,009,144.72, an increase from 64,149,654.93 in the previous year[27] - The net cash flow from financing activities was 1,570,971,039.55, compared to -7,571,607.58 in the previous year, indicating a strong inflow[27] Assets and Liabilities - Total assets at the end of Q1 2022 reached CNY 2,260,708,946.13, a significant increase of 230.89% from CNY 683,227,154.78 at the end of the previous year[3] - The total current assets amounted to 1,769,711,682.43 RMB, compared to 225,933,322.24 RMB at the start of the year, indicating significant growth[18] - The total liabilities decreased from 153,299,903.71 RMB to 82,934,901.82 RMB, showing improved financial health[19] - The company's total assets reached 2,260,708,946.13 RMB, up from 683,227,154.78 RMB at the beginning of the year[18] - The company's equity capital increased significantly, with capital reserves rising to 1,750,029,077.68 RMB from 152,569,334.07 RMB[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,473[10] - The largest shareholder, Ge Jianli, holds 27.17% of the shares, amounting to 26,269,600 shares[10] - The total number of shares after the IPO increased from 72,522,105 to 96,696,140 shares, with a registered capital change from 72,522,105 RMB to 96,696,140 RMB[15] - The company has a total of 73,770,451 shares subject to lock-up agreements, with various release dates[14] Operating Expenses - Operating expenses increased significantly, with sales expenses rising by 119.58% to RMB 1,657,986.57, primarily due to increased marketing efforts and insurance costs[8] - Total operating costs for Q1 2022 were CNY 79,398,196.77, up 25.5% from CNY 63,275,046.96 in Q1 2021[22] - Cash outflow for employee compensation was 17,256,124.91, compared to 11,602,105.45 in the same period last year[27] Investment Activities - Investment income for the quarter was RMB 835,337.26, reflecting a 100% increase attributed to financial management income from raised funds[8] - The cash inflow from investment activities was 51,102,377.26, compared to 107,864.08 in the previous year[27] - The company recorded a significant increase in cash outflow for purchasing goods and services, which rose by 95.91% to RMB 66,040,231.08 due to increased raw material procurement[8] Government Subsidies - The company received government subsidies amounting to CNY 1,871,043.17 during the reporting period[5] Earnings Per Share - The company reported a basic earnings per share of CNY 0.2713, down 6.03% from CNY 0.2887 in the same period last year[3] - Basic earnings per share for Q1 2022 were CNY 0.2713, slightly down from CNY 0.2887 in the previous year[24]